

	CRITERES DE SELECTION ETUDE TARGIT B	Identité patient (coller étiquette patient)
Version 1.0 du 24/10/2021	Investigateur en charge du patient : PI : Dr Etienne MARTIN Mail : emartin@cgfl.fr <i>A contacter pour adresser/inclure patient externe au CGFL</i>	Arc : Amandine CHATELLE Poste : 3538

« TARGIT B »

An international randomised controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence.




	CRITERES DE SELECTION ETUDE TARGIT B	Identité patient (coller étiquette patient)
Version 1.0 du 24/10/2021	Investigateur en charge du patient : PI : Dr Etienne MARTIN Mail : emartin@cgfl.fr <i>A contacter pour adresser/inclure patient externe au CGFL</i>	Arc : Amandine CHATELLE Poste : 3538

VALIDATION DES CRITERES DE SELECTION

Critères d'inclusion :

Less than 46 years of age	<input type="checkbox"/> oui <input type="checkbox"/> non
More than 45 years of age and with one or more of the following poor prognostic factors: a) Grade 3 b) ER and/or PgR negative c) lobular carcinoma d) extensive intraductal component (EIC) e) lymphovascular invasion f) axillary nodal involvement g) more than one tumour in the breast but still suitable for breast conserving surgery through a single specimen h) any factor or a combination of factors that puts the patient at a higher risk of local recurrence as per the current local guidelines : e.g., those who need a tumour bed boost or those <i>not</i> suitable for TARGIT-Alone as standard treatment	<input type="checkbox"/> oui <input type="checkbox"/> non
Those patients with large tumours which have responded to neo-adjuvant chemo- or hormone therapy that is given in an attempt to shrink the tumour, and are now suitable for breast conserving surgery as a result. Note. It is recommended that hormone receptor status (at least ER) is known before randomisation. Patients with either HER2 positive or HER2 negative tumours can be included. The initial determination of characteristics of the tumour should be made by core biopsy, or fine needle aspiration cytology (FNAC) if this is local practice.	<input type="checkbox"/> oui <input type="checkbox"/> non
Indication for conservative surgery	<input type="checkbox"/> oui <input type="checkbox"/> non
Indication of radiotherapy on the entire mammary gland	<input type="checkbox"/> oui <input type="checkbox"/> non
Signed free inform consent	<input type="checkbox"/> oui <input type="checkbox"/> non

	CRITERES DE SELECTION ETUDE TARGIT B	Identité patient (coller étiquette patient)
Version 1.0 du 24/10/2021	Investigateur en charge du patient : PI : Dr Etienne MARTIN Mail : emartin@cgfl.fr <i>A contacter pour adresser/inclure patient externe au CGFL</i>	Arc : Amandine CHATELLE Poste : 3538

Possibility of follow up for at least 10 years according to standard procedures	<input type="checkbox"/> oui <input type="checkbox"/> non
Histologically confirmed breast carcinoma	<input type="checkbox"/> oui <input type="checkbox"/> non

Critères de non inclusion :

Bilateral breast cancer at the time of diagnosis	<input type="checkbox"/> oui <input type="checkbox"/> non
Patients with any severe concomitant disease that may limit their life expectancy	<input type="checkbox"/> oui <input type="checkbox"/> non
Previous history of malignant disease does not preclude entry if the expectation of relapsefree survival at 10 years is 90% or greater (e.g., non-melanoma skin cancer, CIN etc.).	<input type="checkbox"/> oui <input type="checkbox"/> non

Date : _____

Signature de l'investigateur : _____